Trial Profile
Phase II Study With Gefitinib (Sequentially) Following Gemcitabine/Cisplatin as Induction Regimen for Patients With Stage IIIA N2 NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Oct 2012
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Aug 2005 New trial record.